Akın KAYA, Uğur GÖNÜLLÜ, İsmail SAVAŞ, Özlem Ural GÜRKAN, Banu ERİŞ

Küçük hücreli dışı akciğer kanserli hastalarda serum intraselüler adezyon molekülü (sICAM-1)

Son yıllarda kanserlerde değişik oranlarda artmış adezyon molekülleri ekspresyonu bildirilmektedir. Serum intraselüler adezyon molekülü ICAM-1'in tümör invazyonu ve metastaz gelişiminde rolü olduğunu gösteren çalışmalar artmaktadır. Biz Küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda serum ICAM-1 konsantrasyonunu ELISA yöntemi ile ölçtük ve klinik değerini araştırdık. Ellibeş KHDAK'li hastada ve 19 sağlıklı kontrol grubunda sICAM-1 düzeyi ölçüldü. Kanserli grupta serum ICAM-1 ortalama değeri 334.76 ± 114.24 ölçülürken, kontrol grubunda 254.15 ± 57.40 bulundu (p< 0.01). Akciğer kanserinin histolojik tipleri ile sICAM-1 düzeyi arasında anlamlı korelasyon saptandı. Hastalığın evresi ve tümör çapı ile istatistiksel fark gösterilmedi. Serum ICAM-1 düzeyi yüksek olanlarda yaşam süresi daha kısa olsa da aradaki fark istatistiksel olarak anlamlı çıkmadı. Bizim sonuçlarımıza göre KHDAK'de serum ICAM-1 ölçümü hastalığın serolojik tanısında kullanılabilir.

Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer

Recently, abnormal expression of great variety of adhesion molecules has been reported in malignancy. Intercellular adhesion molecule-1 (ICAM-1) has been suggested to play role in the process of tumour invasion and distant metastasis. We analysed serum ICAM-1 concentrations by an enzyme-linked immunosorbent assay (ELISA) and investigated the clinical usefullness of these determinations in patient with non-small cell lung cancer (NSCLC). The mean serum concentrations soluble ICAM-1 in 55 patient with NSCLC was 334.76 ± 114.24 whereas it was in 254.15 ± 57.40 healty controls. The differences in mean serum concentrations between control subjects and NSCLC patients were significant (p< 0.01). No difference was observed between histological tumour types, stages and tumour sizes with regard to ICAM-1 levels. The overall survival of patients with low ICAM-1 levels tended to be longer than those of patients with high concentrations, although the difference was not significant. In conclusion our results suggest that the measurement of ICAM-1 in patients with NSCLC may be usefull for serological diagnosis.

PDF

___

1. Frenette PS, WagnerDD. Adhesion molecules-part I. New Engl J Med 1996; 334:1526-29.
2. Frenette PS, Wagner DD. Adhesion molecules- Part II.New Engl J Med 1996; 335: 43-5.
3. Laffon A, Gonzales-Amaro R. Cell adhesion molecules. An overview. Br J Rheumatol 1995;34: 1101-4.
4. Albelda SM. Biology of disease. Role ofintegrlns and other adhesion molecules in tumor progreslon and metastasis. Lab Inuest 1993; 68: 4-17.
5. Pauli BU, Augustin-Voss HG, El-sabban ME, Johnson RC, Hammer DA. Organ preference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Reu 1990; 9:175-89,
6. Ishii Y, Kitamura S. Soluble Intercellular adhesion molecule-1 as an early detection marker for radiation pneumonltis. Eur Respir J 1999; 13: 733-8.
7. Harning R, Mainolfi E, Bystryn JC, et at. Serum leuels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51:5003-5.
8. Christiansen I, Gidlof C, Kalkner KM, et al. Elevated serum leuels of soluble ICAM-1 In non-Hodgkin's lymphomas correlate with tumour burden, disease actiuity and other prognostic markers. Br J Haematol 1996; 92: 639-46.
9. Christiansen I, Gidlof C, Wallgren AC, et al. Serum leuels of soluble Intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994; 84:3010-6.
10. Christiansen I, Enblad G, Kalkner KM, et at Soluble ICAM-1 in Hodgkin's disease: A promising independent predictive marker for survival. Leuk Lymphoma 1995; 19: 3129-39.
11. Gruss HJ, Dolken G, Brach MA, et al. Serum levels of circulating ICAM'1 are increased in Hodgkin's disease. Leukemia 1993; 7: 1245.
12. Tsujisaki M, Imai K, Hirata H, et at Detection of 1 (ICAM-1) during the development of Invasion an carcinoma. J Cancer Res Clin Oncol 1992; 18: 609-61.
13. Banks RE, Gearing AJH, Hemingway IK, et at Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule 1 (VCAM-İ) In human malignancies. Br J Cancer 1993; 68: 122-4.
14. Sprenger A, Schardt C, Rotsch M, et al. Soluble Intercellular adhesion molecule-1 in patients with lung cancer and benign lung diseases. J Cancer Res Clin Oncol 1997; 123: 632-8.
15. Tauchl O, Gabazza EC, Kobayashi T, et al. Circulating intercellular adhesion molecule-1in patients with lung cancer. Intern Med 1997; 36: 14-8.
16. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility classl and Class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: Frequency and prognostic significance, Eur J of Cancer 1994; 30: 376-81.
17. Grothey A, Heistermann P, Phillippou S, et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-19 in patients with non-small-cell lung cancer: Correlation with histolgical expression of ICAM-1 and tumour stage. Br J Cancer 1998; 77: 801-7.
18. Osaki T, Mitsudomi T, Yoshida Y, et al. Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. Surgical Oncol 1996; 5: 107-13.
19. Benekli M, Güllü IH, Tekuzman G, et al. Circulating intercellular adhesion molecute-1 and E-selectin levels In gastric cancer. BrJ Cancer 1998; 8:267-71.